We need to be aware of our strengths. Import substitution is definitely needed, but a breakthrough takes radiopharmaceuticals and R&D for immunobiologicals. <…> As for these competencies, we can move forward and create new things faster — Mikhail Murashko, Minister of Health of the Russian Federation.
The future holds a transition to truly personalized medicine. What does it mean? It means influencing each person's body by understanding their absolute uniqueness, unique biological codes, genetic, various omics [technologies based on advances in genomics. – Ed]. <...> many of our centres are working in this direction — Veronika Skvortsova, Head, Federal Medical-Biological Agency of the Russian Federation.
Today we are building a world-class centre. It will offer digital biodesign and personalised healthcare, which will make it possible to prepare software for early diagnosis, treatment and prognosis for kidney cancer, lung cancer, colorectal cancer, hypertension, myocardial infarction in the near future. This is a big task, it will not be solved tomorrow – by 2025, as far as we have been funded. This creation of digital duplicates of diseases is a decades-long task — Petr Glybochko, Rector, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation.
In order for us to thrust into the future and to be at the forefront of it, it is not enough to follow an extensive route, i.e. creating what already exists in the West, copying those technologies that are already out there. This is a necessary condition but it is not sufficient. To be ahead of the curve, we must introduce fundamentally new approaches, technologies which are not yet widely used today and are of a fundamentally new nature — Sergei Lukyanov, Rector, Pirogov Russian National Research Medical University.